QLGN - Qualigen Therapeutics Inc
4.21
0.010 0.238%
Share volume: 11,533
Last Updated: Wed 22 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.35%
PREVIOUS CLOSE
CHG
CHG%
$4.20
0.03
0.01%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2024-07-02 | 2023-08-14 | 2023-11-14 | 2024-11-14 | 2024-07-02 | 2024-08-14 | 2024-11-14 | |
| Assets | ||||||||
| Total Assets | 15.914 M | 13.150 M | 4.316 M | 2.033 M | 1.003 M | 534.410 K | 2.313 M | |
| Current Assets | 7.538 M | 4.863 M | 3.450 M | 1.167 M | 1.003 M | 534.410 K | 2.313 M | |
| Inventories | 1.481 M | 1.563 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 4.363 M | 1.342 M | 2.074 M | 401.803 K | 93.217 K | 118.685 K | 388.152 K | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 522.408 K | 498.647 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 7.854 M | 7.783 M | 866.481 K | 866.481 K | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 15.914 M | 13.150 M | 4.316 M | 2.033 M | 1.003 M | 534.410 K | 2.313 M | |
| Total liabilities | 9.714 M | 9.842 M | 5.957 M | 4.137 M | 4.525 M | 4.812 M | 4.454 M | |
| Total current liabilities | 8.244 M | 8.494 M | 5.957 M | 4.137 M | 4.525 M | 4.812 M | 4.454 M | |
| Accounts Payable | 899.948 K | 1.756 M | 1.572 M | 2.223 M | 1.801 M | 1.854 M | 1.638 M | |
| Other liabilities | 1.236 M | 1.169 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 1.236 M | 1.169 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 4.869 M | 2.034 M | -1.641 M | -2.104 M | -3.522 M | -4.278 M | -2.141 M | |
| Common stock | 111.930 M | 112.598 M | 112.712 M | 114.699 M | 115.313 M | 116.134 M | 120.065 M | |
| Retained earnings | -107.231 M | -110.696 M | -114.352 M | -116.802 M | -118.835 M | -120.412 M | -122.206 M |